Official Information Act response: adrenaline auto-injector cost utility analysis


20 May 2019 - PHARMAC responds to a request for any cost utility analyses performed by PHARMAC in relation to adrenaline auto-injectors (such as EpiPen) for the treatment of anaphylaxis, from 2004 onward.

Read PHARMAC's Technology Assessment Report for adrenaline auto-injector (EpiPen, Anapen, Twinject and others) for first aid treatment of anaphylaxis.

Read PHARMAC report

Michael Wonder

Posted by:

Michael Wonder